NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis → Biden’s Tax Plan Could Destroy Your Retirement Savings! (From GoldenCrest Metals) (Ad) Free RPHM Stock Alerts $1.66 -0.04 (-2.35%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.62▼$1.7050-Day Range$1.59▼$1.9052-Week Range$0.98▼$9.21Volume148,235 shsAverage Volume296,749 shsMarket Capitalization$55.48 millionP/E RatioN/ADividend YieldN/APrice Target$11.01 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Reneo Pharmaceuticals alerts: Email Address Reneo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingReduce1.88 Rating ScoreUpside/Downside559.4% Upside$11.01 Price TargetShort InterestBearish16.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 3 Articles This WeekInsider TradingAcquiring Shares$637,993 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector486th out of 917 stocksPharmaceutical Preparations Industry225th out of 431 stocks 2.9 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReneo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Reneo Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.13% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently decreased by 3.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 3.4 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Reneo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $637,993.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reneo Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.83) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reneo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.Learn More Today About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More RPHM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPHM Stock News HeadlinesMay 17, 2024 | insidertrades.comReneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Acquires 414,281 SharesJune 11 at 1:50 AM | americanbankingnews.comBrokerages Set Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) PT at $11.01May 14, 2024 | markets.businessinsider.comMitchell Kapoor’s Hold Rating on Reneo Pharmaceuticals Amid OnKure Merger and Oncology Pipeline PotentialMay 14, 2024 | businesswire.comRENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMMay 13, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHMMay 13, 2024 | finance.yahoo.comReneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares RiseMay 13, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHMMay 13, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKureMay 13, 2024 | businesswire.comRPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to ShareholdersMay 13, 2024 | markets.businessinsider.comReneo Pharmaceuticals, OnKure To MergeMay 13, 2024 | marketwatch.comReneo Pharmaceuticals Sets Reverse Merger With OnKureMay 13, 2024 | msn.comReneo Pharmaceuticals gains on deal to merge with OnKureMay 13, 2024 | globenewswire.comReneo Pharmaceuticals and OnKure Announce Proposed MergerMay 10, 2024 | markets.businessinsider.comMaintaining Hold on Reneo Pharmaceuticals Amidst Strategic Uncertainties and Pipeline SetbacksMay 7, 2024 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | investorplace.comRPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024May 7, 2024 | finance.yahoo.comReneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comReneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsApril 14, 2024 | thestreet.comReneo Pharmaceuticals Inc.March 31, 2024 | markets.businessinsider.comSell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price TargetMarch 28, 2024 | benzinga.comReneo Pharmaceuticals: Q4 Earnings InsightsMarch 28, 2024 | investorplace.comRPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023March 28, 2024 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateMarch 28, 2024 | globenewswire.comReneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateFebruary 14, 2024 | uk.finance.yahoo.comReneo Pharmaceuticals, Inc. (RPHM)See More Headlines Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/14/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$11.01 High Stock Price Target$35.55 Low Stock Price Target$1.50 Potential Upside/Downside+563.4%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.76% Return on Assets-60.10% Debt Debt-to-Equity RatioN/A Current Ratio29.83 Quick Ratio29.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book0.62Miscellaneous Outstanding Shares33,420,000Free Float27,439,000Market Cap$55.48 million OptionableOptionable Beta0.22 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 71)Founder & Executive Chairman Comp: $100kMr. Gregory J. Flesher (Age 54)President, CEO & Director Comp: $569.7kDr. Alejandro Dorenbaum M.D. (Age 63)Chief Medical Officer Comp: $466.23kMs. Ashley F. Hall J.D. (Age 52)Chief Development Officer Comp: $447.1kMs. Jennifer P. LamSVP of Finance & Administration and Principal Financial & Accounting OfficerMr. Michael P. Cruse (Age 52)Chief Operating Officer Comp: $535.47kMore ExecutivesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTCitius PharmaceuticalsNASDAQ:CTXRMenlo TherapeuticsNASDAQ:FOMXSpectrum PharmaceuticalsNASDAQ:SPPIAkebia TherapeuticsNASDAQ:AKBAView All CompetitorsInsiders & InstitutionsIkarian Capital LLCSold 432,600 shares on 5/17/2024Ownership: 0.000%Braden Michael LeonardBought 414,281 shares on 5/14/2024Total: $637,992.74 ($1.54/share)Marquette Asset Management LLCBought 73,770 shares on 5/7/2024Ownership: 0.221%Fifth Lane Capital LPSold 7,365 shares on 5/2/2024Ownership: 0.098%BML Capital Management LLCBought 863,684 shares on 4/23/2024Ownership: 6.517%View All Insider TransactionsView All Institutional Transactions RPHM Stock Analysis - Frequently Asked Questions Should I buy or sell Reneo Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" RPHM shares. View RPHM analyst ratings or view top-rated stocks. What is Reneo Pharmaceuticals' stock price target for 2024? 8 brokers have issued 1-year price targets for Reneo Pharmaceuticals' shares. Their RPHM share price targets range from $1.50 to $35.55. On average, they predict the company's stock price to reach $11.01 in the next year. This suggests a possible upside of 559.4% from the stock's current price. View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts. How have RPHM shares performed in 2024? Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of the year. Since then, RPHM stock has increased by 4.4% and is now trading at $1.67. View the best growth stocks for 2024 here. When is Reneo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our RPHM earnings forecast. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Tuesday, May, 7th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. When did Reneo Pharmaceuticals IPO? Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Reneo Pharmaceuticals' major shareholders? Reneo Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (6.52%), Marquette Asset Management LLC (0.22%), Fifth Lane Capital LP (0.10%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Braden Michael Leonard, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell and Vineet R Jindal. View institutional ownership trends. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPHM) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.